R
RTW Investments, LP
+ 持有ZLAB
-11.31%
3個月報酬率
$23.190
-0.315 (-1.36%)收盤時
Loading chart…
- 最高
- 24.640
- 開盤
- 24.550
- 成交量加權均價
- 23.66
- 成交量
- 843.23K
- 市值
- 1.73B
- 最低
- 23.140
- 成交金額
- 19.95M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -6.11
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
AI 分析 of Zai Lab Ltd (ZLAB)
持有Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
分析師評級（3）
上檔空間 +106.68%
買進
2 買進
1 持有
0 賣出
目前: 23.19
最低
25.70
平均
47.93
最高
74.00
JPMorgan
增持
$36
2026-08-27
JPMorgan
2026-08-27
目標價
$36
增持
Citi
買進
$45
2026-08-07
Citi
2026-08-07
目標價
$45
買進
Citi
買進
$44
2026-05-08
Citi
2026-05-08
目標價
$44
買進
JPMorgan
增持
$32
2026-03-18
JPMorgan
2026-03-18
目標價
$32
增持
Cantor Fitzgerald
增持
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
目標價
$37
增持
估值指標
Zai Lab Ltd（ZLAB）目前預期本益比為 0.00，5 年平均預期本益比為 -16.19。
持有 ZLAB 的大戶
事件時間軸
資訊
9.010-14NewsfilterZai Lab to Present ZL-1503 Clinical Trial Data at ACAAI 2026
9.509-17CNBCChinese AI Companies Struggle with Revenue Growth
- 8.509-17Newsfilter
Chinese AI Models Generate Only 10% of Revenue Compared to U.S. Rivals
8.509-14CNBCZ.ai Plans to Raise $5 Billion Through Share Placement and Bonds
- 8.509-14Newsfilter
Z.ai Plans $5 Billion Fundraising, Shares Plunge Over 10%
ZLAB 常見問題 —— 由 Alphio AI 解答
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。